ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.10−0.05 (-4.35%)
Close on Nov 18, 2026Market cap $115.90MP/E –Yield –
ProQR Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ProQR Therapeutics's revenue for the twelve months ending Jun 30, 2026 was €18.36M, up 11.4% year over year. For fiscal 2025 it was €15.91M, down 15.9% from the year before. The highest annual figure on record is €18.91M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €15.91M | -15.9% |
| FY2024 | Dec 31, 2024 | €18.91M | +190.2% |
| FY2023 | Dec 31, 2023 | €6.51M | +81.2% |
| FY2022 | Dec 31, 2022 | €3.59M | +169.2% |
| FY2021 | Dec 31, 2021 | €1.34M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €8.76M | +129.5% |
| Q1 FY2026 | Mar 31, 2026 | €2.03M | -55.0% |
| Q4 FY2025 | Dec 31, 2025 | €4.69M | +8.8% |
| Q3 FY2025 | Sep 30, 2025 | €2.88M | -25.0% |
| Q2 FY2025 | Jun 30, 2025 | €3.82M | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | €4.52M | +1.6% |
| Q4 FY2024 | Dec 31, 2024 | €4.31M | +31.2% |
| Q3 FY2024 | Sep 30, 2024 | €3.84M | +180.5% |
| Q2 FY2024 | Jun 30, 2024 | €6.31M | +423.2% |
| Q1 FY2024 | Mar 31, 2024 | €4.45M | +579.4% |
| Q4 FY2023 | Dec 31, 2023 | €3.28M | +356.1% |
| Q3 FY2023 | Sep 30, 2023 | €1.37M | +68.3% |
| Q2 FY2023 | Jun 30, 2023 | €1.21M | +29.6% |
| Q1 FY2023 | Mar 31, 2023 | €655.00K | -42.0% |
| Q4 FY2022 | Dec 31, 2022 | €720.00K | +201.3% |
| Q3 FY2022 | Sep 30, 2022 | €814.00K | -6.7% |
| Q2 FY2022 | Jun 30, 2022 | €930.00K | +282.7% |
| Q1 FY2022 | Mar 31, 2022 | €1.13M | – |
| Q4 FY2021 | Dec 31, 2021 | €239.00K | – |
| Q3 FY2021 | Sep 30, 2021 | €872.00K | – |
| Q2 FY2021 | Jun 30, 2021 | €243.00K | – |
See a number that looks wrong?